Hyderabad, November 25, 2018: Unichem Laboratories Limited (‘Unichem’) today announced that the company has entered into an agreement to acquire 20% equity stake in the API and intermediate business of Hyderabad based Optimus group (‘Optimus’).
The transaction will give Unichem access to Optimus’ US FDA approved API manufacturing facilities, and at the same time, Optimus will gain from the extensive knowledge base and industry best practices of Unichem, making the deal a win-win for both Unichem and Optimus.
Trans-Continental Capital Advisors Private Limited (‘TCCA’) and Genesis Management Consultancy Services Private Limited (‘GMCS’) acted as financial advisors to the transaction. TCCA, a Mumbai based advisory firm has recently acted as an advisor in the INR 500 crores worth acquisition of Kimplas Piping Systems by Germany’s Norma group.
Corporate Comm India(CCI NewsWire)
· World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…
Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Winter weather brings a host…
By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…
Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…
Coimbatore, October 30, 2024: Sri Ramakrishna Hospital’s Neurology experts observes “World Stroke Day” on October…